Karyopharm Therapeutics (KPTI) Misses Q1 EPS by 251c
Tweet
Share
E-mailGet Alerts KPTI Hot Sheet
Join SI Premium – FREE
Karyopharm Therapeutics (NASDAQ: KPTI) reported Q1 EPS of ($2.77), $2.51 worse than the analyst estimate of ($0.26). Revenue for the quarter came in at $30.01 million versus the consensus estimate of $37.84 million.
For earnings history and earnings-related data on Karyopharm Therapeutics (KPTI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- KB Home (KBH) Tops Q3 EPS by 16c
- FirstLine Venture Partners acquires $150,000 in Forward Water units
- Decoy Therapeutics corrects warrant exercisability in inducement deal
Create E-mail Alert Related Categories
Earnings, FDARelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
